Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is set to announce third quarter earning results on Thursday 5th November 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, REGN to report 3Q20 income of $ 7.13 per share.
For the full year, analysts anticipate top line of $ 8176.80 million, while looking forward to income of $ 28.75 per share bottom line.
Previous Quarter Performance
Regeneron Pharmaceuticals, Inc. unfold income for the second quarter of $ 7.16 per share, from the revenue of $ 1,952.00 million. The quarterly earnings 18.94 percent while revenues developed 0.95 percent compared with the same quarter last year.
The consensus estimates are income of $ 5.98 per share from $ 1741.97 million in revenue. The bottom line results beat street analysts by $ 1.18 or 19.73 percent, at the same time, top line results outshined analysts by $ 210.03 million or 12.06 percent.
Stock Performance
Shares of Regeneron Pharmaceuticals, Inc. traded up $ 29.95 or 5.38 percent on Wednesday, reaching $ 587.14 with volume of 1.08 million shares. Regeneron Pharmaceuticals, Inc. has traded high as $ 593.96 and has cracked $ 576.00 on the downward trend
The closing price of $ 587.14, representing a 71.83 % increase from the 52 week low of $ 324.27 and a 16.17 % decrease over the 52 week high of $ 664.64.
The company has a market capital of $ 62.47 billion and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 13th October 2020, maintained by Morgan Stanley at Equal-Weight rating, with $ 609.00 target price.
- On 6th October 2020, maintained by SVB Leerink at Outperform rating, with $ 650.00 target price.
- On 5th October 2020, upgraded by Cantor Fitzgerald to Overweight from Neutral rating.
Conference Call
Regeneron Pharmaceuticals, Inc. will be hosting a conference call at 8:30 AM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.regeneron.com
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The companys products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults.
